Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Bioxytran ( (BIXT) ) has shared an update.
On February 10, 2026, Bioxytran signed a commercial distribution agreement with Khoury Medical LTD for A-SUQAR, a chewable dietary supplement containing its proprietary partially hydrolyzed guar gum formulation to support healthy post-meal blood sugar levels. The deal positions Khoury Medical as the commercializer in permitted markets while Bioxytran retains manufacturing via an OEM and full ownership of its intellectual property.
Announced publicly on February 17, 2026, the agreement marks a strategic shift for Bioxytran from a pure development-stage biotech to one with potential recurring commercial revenue from nutraceutical products. The structure, including potential volume-based exclusivity and a focus solely on non-pharmaceutical dietary products, preserves Bioxytran’s ability to advance higher-value pharmaceutical and antiviral programs built on its galectin-targeting platform, which has been supported by recent positive Phase 2 results for its antiviral candidate ProLectin-M.
Operationally, Khoury Medical will lead regulatory registration, marketing, and distribution, allowing Bioxytran to pursue a capital-efficient commercial model while using A-SUQAR as real-world validation of its carbohydrate-based galectin technology. Initial commercial shipments are expected to begin after completion of standard launch preparations, offering both companies an opportunity to address consumer demand for metabolic health solutions through established retail and pharmacy channels.
More about Bioxytran
Bioxytran, Inc. is a biotechnology company developing carbohydrate-based technologies that target galectins and related biological pathways across infectious disease, metabolic health, inflammation, and oncology. Its platform supports both pharmaceutical and nutraceutical programs, including commercial-ready products and licensing opportunities focused on science-driven health applications.
Khoury Medical LTD is a health-focused company specializing in plant-derived dietary supplements, partnering with technology providers to deliver differentiated, science-based products through consumer and pharmacy channels. Its collaboration model emphasizes commercialization of supplements that address specific metabolic and wellness needs.
A-SUQAR is a chewable tablet taken before meals, formulated with Bioxytran’s proprietary partially hydrolyzed guar gum to help reduce blood sugar and support healthy post-meal blood glucose levels in line with dietary supplement regulations. The product targets consumers seeking non-pharmaceutical options for managing postprandial blood sugar as part of broader metabolic health strategies.
Average Trading Volume: 173,254
Technical Sentiment Signal: Sell
Current Market Cap: $4.8M
Learn more about BIXT stock on TipRanks’ Stock Analysis page.